Eyam Health Inc. today announced the publication of peer-reviewed research in Nature Communications describing Gemini™, a binary self-amplifying genetic expression platform that can be deployed as ...

New therapeutics in development for autoimmune disease and oncologyLead therapeutic BRZ-101 designed to restore immune tolerance in type 1 diabetes, advancing into IND-enabling studiesExpanding ...

The same groundbreaking technology that enabled rapid COVID-19 vaccine development is now poised to revolutionize medicine in ways that seemed impossible just a few years ago. Messenger RNA vaccines ...

Emerging modalities such as self-amplifying and circular RNA, expanding oncology and rare-disease applications, and scalable manufacturing are creating high-growth investment avenues, supported by ...

Johns Hopkins Medicine laboratory scientists say they have developed a potential new way to treat a variety of rare genetic diseases marked by too low levels of specific cellular proteins. To boost ...

Moderna says its experimental mRNA influenza vaccine, mRNA-1010, showed more than 30% greater relative vaccine efficacy against influenza A than a licensed egg-based flu shot in a large Phase 3 trial ...

Discover six RNAi biotech companies helping to drive momentum in a field that can precisely target disease at its genetic root.

A new case report was published in Volume 17 of Oncotarget on February 6, 2026, titled “Exploring the potential link between ...

Will consider data that includes "the experience of individuals," FDA commissioner says ...

– Research collaboration with Praxis Precision Medicines to develop LNP formulations for ASO delivery – MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines ...

Some genetic mutations that are expected to completely stop a gene from working surprisingly cause only mild or even no symptoms. Researchers in previous studies have discovered one reason why: cells ...